ALIGN TECHNOLOGY CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands except per share data)

N.A. Ortho Revenue YOY % growth QOO % growth N.A GP Revenue YOY % growth QOO & arowth	Q1 2008 \$ 22,551 5.8% 6.4% 33,935 16.0%	Q2 2008 \$ 22,994 -7.0% 2.0% 35,577 -0.4% 4.8%	Q3 2008 \$ 21,951 -1.4% -4.5% 33,861 -0.8% -4.8%	Q4 2008 \$ 20,826 -1.8% -5.1% 32,095 -1.8% -5.2%	FY 2008 \$ 88,322 -1.3% 135,468 2.8%	Q1 2009 \$ 21,087 -6.5% 1.3% 30,916 -8.9% -3.7%	Q2 2009 \$ 21,574 -6.2% 2.3% 31,756 -10.7%	Q3 2009 \$ 22,722 3.5% 5.3% 33,908 0.1% 6.8%	Q4 2009 \$ 25,036 20,2% 10,2% 36,172 12,7% 6,7%	YTD 2009 \$ 90,419	Q1 2010 \$ 28,195 33.7% 12.6% 37,200 20.3% 2.8%
International Non-case Revenue*	14,196 4,094	16,436 4,895	15,128 4,233	16,248 4,956	62,008 18,178	14,267 3,862	18,058 4,928	18,460 4,179	21,259 4,149	72,044 17,118	20,027 4,668
Revenues YOY % growth QOQ % growth	74,776 17.3% 3.1%	79,902 4.3% 6.9%	75,173 5.2% -5.9%	74,125 2.2% -1.4%	303,976 6.9%	70,132 -6.2% -5.4%	76,316 -4.5% 8.8%	79,269 5.4% 3.9%	86,616 16.9% 9.3%	312,333	90,090 28.5% 4.0%
Cost of revenues	19,608	20,243	18,766	20,233	78,850	17,425	18,338	20,268	22,810	78,841	20,380
Gross Profit	55,168	59,659	56,407	53,892	225,126	52,707	57,978	59,001	63,806	233,492	69,710
Operating Expenses: Sales and marketing General and administrative Research and development Restructuring Charges Patient first program Litigation settlement costs Total operating expenses	28,059 15,188 7,295 - - - 50,542	32,464 16,322 7,001 - - - - 55,787	28,214 14,395 5,918 2,189 - 50,716	26,325 16,249 5,951 4,042 - - 52,567	115,062 62,154 26,165 6,231 - 209,612	27,854 13,468 5,191 910 - - - 47,423	29,108 16,539 5,669 409 - - 51,725	27,687 16,224 5,611 - - - - - - - - - - - - - - - - - -	27,893 15,487 5,781 - - - - 49,161	112,542 61,718 22,252 1,319 - 69,673 267,504	27,946 14,951 6,116 - - - - 49,013
Profit (loss) from operations Interest and other income (expense), net Profit (loss) before provision for income taxes Provision for (benefit) from income taxes Net profit (loss) Net profit (loss) per share - basic - diluted	4,626 966 5,592 288 5,304 \$ 0.08 \$ 0.07	3,872 443 4,315 285 4,030 \$ 0,06 \$ 0,06	5,691 264 5,955 798 5,157 \$ 0.08 \$ 0.08	1,325 (111) 1,214 (64,282) 65,496 \$ 0,99 \$ 0,98	15,514 1,562 17,076 (62,911) 79,987 \$ 1,20 \$ 1,18	5,284 148 5,432 2,796 2,636 \$ 0.04 \$ 0.04	6,253 557 6,810 2,265 4,545 \$ 0.07 \$ 0.07	(60,194) (271) (60,465) (10,523) (49,942) \$ (0,72) \$ (0,72)	14,645 (315) 14,330 2,838 11,492 \$ 0,15 \$ 0,15	(34,012) 119 (33,893) (2,624) (31,269) \$ (0,45) \$ (0,45)	20,697 (553) 20,144 5,214 14,930 \$ 0,20 \$ 0,19
Shares used in computing net profit (loss) per share - basic - diluted	69.053 70,860	68.581 69,916	67.367 68,704	66.440 66,816	66.812 68,064	65.983 66,447	66.285 67,373	69.528 69,528	74.482 76.831	69.094 69,094	75.166 77,597
Margin Analysis: Gross Margin Sales and Marketing General and administrative Research and development Restructuring Patients First Program and Settlement Costs (credits) Operating Margin Net Margin	73.8% 37.5% 20.3% 9.8% 0.0% 6.2% 7.1%	74.7% 40.6% 20.4% 8.8% 0.0% 0.0% 4.8% 5.0%	75.0% 37.5% 19.1% 7.9% 2.9% 0.0% 7.6% 6.9%	72.7% 35.5% 21.9% 8.0% 5.5% 0.0% 1.8% 88.4%	74.1% 37.9% 20.4% 8.6% 2.0% 0.0% 5.1% 26.3%	75.2% 39.7% 19.2% 7.4% 1.3% 0.0% 7.5% 3.8%	76.0% 38.1% 21.7% 7.4% 0.5% 0.0% 8.2% 6.0%	74.4% 34.9% 20.5% 7.1% 0.0% 87.9% -75.9% -63.0%	73.7% 32.2% 17.9% 6.7% 0.0% 0.0% 16.9% 13.3%	74.8% 36.0% 19.8% 7.1% 0.4% 0.0% -10.9% -10.0%	77.4% 31.0% 16.6% 6.8% 0.0% 0.0% 23.0% 16.6%
Year Over Year Analysis Revenue Profit (Loss) from Operations Operating Expense Net Profit (Loss)	17.3% -33.9% 28.8% -24.0%	4.3% -71.2% 30.0% -70.4%	5.2% -32.2% 12.9% -45.5%	2.2% -73.6% 8.7% 1055.5%	6.9% -54.2% 19.5% 123.9%	-6.2% 14.2% -6.2% -50.3%	-4.5% 61.5% -7.3% 12.8%	5.4% -1157.7% 135.0% -1068.4%	16.9% 1005.3% -6.5% -82.5%	2.7% -319.2% 27.6% -139.1%	28.5% 466.4% 3.4% 466.4%
Quarter Over Quarter Analysis (Sequential) Revenue Profit (Loss) from Operations Operating Expense Net Profit (Loss)	3.1% -7.7% 4.5% -6.4%	6.9% -16.3% 10.4% -24.0%	-5.9% 47.0% -9.1% 28.0%	-1.4% -76.7% 3.6% 1170.0%		-5.4% 298.8% -9.8% -96.0%	8.8% 18.3% 9.1% 72.4%	3.9% -1062.6% 130.4% -1198.8%	9.3% -124.3% -58.8% -123.0%		4.0% 29.9% -0.3% 29.9%

^{*} Non-case revenue includes the retainer business, training revenues, and ancillary offerings

ALIGN TECHNOLOGY NON-GAAP CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands except per share data)

	Q1 2008	Q2 2008	Q3 2008	Q4 2008	FY 2008	Q1 2009	Q2 2009	Q3 2009	Q4 2009	YTD 2009	Q1 2010
N.A. Ortho Revenue	\$ 22,551	\$ 22,994	\$ 21,951	\$ 20,826	\$ 88,322	\$ 21,087	\$ 21,574	\$ 22.722	\$ 25,036	\$ 90,419	28,195
YOY % growth	5.8%	-7.0%	-1.4%	-1.8%	-1.3%	-6.5%	-6.2%	3.5%	20.2%		33.7%
QOQ % growth	6.4%	2.0%	-4.5%	-5.1%		1.3%	2.3%	5.3%	10.2%		12.6%
N.A GP Revenue	33,935	35,577	33,861	32,095	135,468	30,916	31,756	33,908	36,172	132,752	37,200
YOY % growth	16.0%	-0.4%	-0.8%	-1.8%	2.8%	-8.9%	-10.7%	0.1%	12.7%		20.3%
QOQ % growth	3.8%	4.8%	-4.8%	-5.2%		-3.7%	2.7%	6.8%	6.7%		2.8%
International	14,196	16,436	15,128	16,248	62,008	14,267	18,058	18,460	21,259	72,044	20,027
Non-case Revenue*	4,094	4,895	4,233	4,956	18,178	3,862	4,928	4,179	4,149	17,118	4,668
Revenues	74,776	79,902	75,173	74,125	303,976	70,132	76,316	79,269	86,616	312,333	90,090
Cost of revenues	19,608	20,243	18,766	20,233	78,850	17,425	18,338	18,362	18,551	72,676	19,553
Gross Profit	55,168	59,659	56,407	53,892	225,126	52,707	57,978	60,907	68,065	239,657	70,537
Operating Expenses:											
Sales and marketing	28,059	32,464	28,214	26,325	115,062	27,854	29,108	27,687	27,893	112,542	27,946
General and administrative	15,188	16,322	14,395	16,249	62,154	13,468	16,539	16,224	15,487	61,718	14,951
Research and development	7,295	7,001	5,918	5,951	26,165	5,191	5,669	5,611	5,781	22,252	6,116
Total operating expenses	50,542	55,787	48,527	48,525	203,381	46,513	51,316	49,522	49,161	196,512	49,013
Profit from operations	4,626	3,872	7,880	5,367	21,745	6,194	6,662	11,385	18,904	43,145	21,524
Interest and other income (expense), net	966	443	264	(111)	1,562	148	557	(271)	(315)	119	(553)
Profit before provision for income taxes	5,592	4,315	8,144	5,256	23,307	6,342	7,219	11,114	18,589	43,264	20,971
Provision for income taxes	288	285	884	369	1,826	3,151	2,392	2,208	6,443	14,194	5,430
Net profit	5,304	4,030	7,260	4,887	21,481	3,191	4,827	8,906	12,146	29,070	15,541
Net profit per share											
- basic	\$ 0.08	\$ 0.06	\$ 0.11	\$ 0.07	\$ 0.32	\$ 0.05	\$ 0.07	\$ 0.13	\$ 0.16	\$ 0.42	\$ 0.21
- diluted	\$ 0.07	\$ 0.06	\$ 0.11	\$ 0.07	\$ 0.32	\$ 0.05	\$ 0.07	\$ 0.13	\$ 0.16	\$ 0.41	\$ 0.20
Shares used in computing net profit per share											
- basic	69,053	68,581	67,367	66,440	66,812	65,983	66,285	69,528	74,482	69,094	75,166
- diluted	70,860	69,916	68,704	66,816	68,064	66,447	67,373	70,926	76,831	70,602	77,597
Margin Analysis:											
Gross Margin	73.8%	74.7%	75.0%	72.7%	74.1%	75.2%	76.0%	76.8%	78.6%	76.7%	78.3%
Operating Margin	6.2%	4.8%	10.5%	7.2%	7.2%	8.8%	8.7%	14.4%	21.8%	13.8%	23.9%
Net Margin	7.1%	5.0%	9.7%	6.6%	7.1%	4.5%	6.3%	11.2%	14.0%	9.3%	17.3%
Year Over Year Analysis											
Revenue	17.3%	4.3%	5.2%	2.2%	6.9%	-6.2%	-4.5%	5.4%	16.9%	2.7%	28.5%
Profit from Operations Net Profit	-11.1% 3.2%	-71.2% -70.4%	-6.1% 23.2%	7.1% 13.8%	-32.2% -36.8%	33.9% -39.8%	72.1% 19.8%	44.5% 22.7%	252.2% 148.5%	98.4% 35.3%	247.5% 387.0%
Neti Tolk	3.270	70.470	20.270	13.070	30.070	33.070	13.070	22.170	140.570	00.070	307.070
Quarter Over Quarter Analysis (Sequential)					1					1 1	
Revenue	3.1%	6.9%	-5.9%	-1.4%	1	-5.4%	8.8%	3.9%	9.3%	1 1	4.0%
Gross Profit	3.3%	8.1%	-5.5%	-4.5%	1	-2.2%	10.0%	5.1%	11.8%	1 1	3.6%
Operating Expense Net Profit	4.5% -6.4%	10.4% -24.0%	-13.0% 80.1%	0.0% 32.7%	1	-4.1% -34.7%	10.3% 51.3%	-3.5% 84.5%	-0.7% 36.4%	1	-0.3% 28.0%
	-0.476	-24.076	00.176	32.1 /6		-54.776	31.376	04.376	30.476		20.076
Reconciliation of GAAP Net Profit (Loss) to non-GAAP Net Profit:											
GAAP Net profit (loss)	5,304	4,030	5,157	65,496	79,987	2,636	4,545	(49,942)	11,492	(31,269)	14,930
Patient first program	-	-	-	-	- 1	-	-			1 : 1	-
Ormco royalties	-	-	-	-	- 1	-	-	1,906	4,259	6,165	827
Litigation settlement costs	-	-	- 0.400	4.040	- 0004	- 040	-	69,673	-	69,673	-
Restructuring	-	-	2,189	4,042 (64,608)	6,231	910	409	-	-	1,319	-
Release of tax valuation allowance Tax impact on non GAAP adjustments			(86)	(64,608)	(64,608) (129)	(355)	(127)	(12,731)	(3,605)	(16,818)	(216)
Non-GAAP net profit	5,304	4,030	7,260	4,887	21,481	3,191	4,827	8,906	12,146	29,070	15,541
Hon Orbit hot profit	5,504	4,000	1,200	4,007	21,401	3,131	4,027	0,300	12,140	25,070	10,041

^{*} Non-case revenue includes the retainer business, training revenues, and ancillary offerings